Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. METHODS: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. RESULTS: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r = -0.84, P<0.001). CONCLUSIONS: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
The Eating Attitudes Test: an index of the symptoms of anorexia nervosa
Garner, D. M., & Garfinkel, P. E. (1979) · Psychological Medicine · doi:10.1017/s0033291700030762 · Cited by 3,543 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationPlasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationObesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Cited by
Items 101–200 of 1,003
Bone, Fat, and Body Composition: Evolving Concepts in the Pathogenesis of Osteoporosis
Rosen, C. J., & Klibanski, A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.11.027 · Cited by 235
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Intravenous Infusion of Peptide YY(3–36) Potently Inhibits Food Intake in Rats
Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2005) · Endocrinology · doi:10.1210/en.2004-1138 · Cited by 231
“The rank order of ED50s [pmol kg 1 min (1)] of these peptides including PYY (3–36) are salmon CT [1], amylin [6], PYY (3–36) [15], CCK8 [18], CT-gene-related peptide [26], and adrenomedullin [35].”
BackgroundSuzuki, K., Jayasena, C. N., & Bloom, S. R. (2012) · Experimental Diabetes Research · doi:10.1155/2012/824305 · Cited by 227
“In both lean and obese human subjects, intravenous administration of PYY3–36 reduces appetite and food intake [16, 17] with observed plasma PYY3–36 levels similar to the physiological levels after a meal; this data suggests that the physiological effect of PYY is to suppress food intake.”
BackgroundSelf-citationGut peptides and the regulation of appetite
Huda, M. S. B., Wilding, J. P. H., & Pinkney, J. H. (2006) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00245.x · Cited by 223
“Obese subjects do not seem to show PYY resistance; PYY3-36 infusions reduce food intake by equal amounts (30–31%) in lean and obese volunteers (79).”
BackgroundRegulation of energy balance by a gut–brain axis and involvement of the gut microbiota
Bauer, P. V., Hamr, S. C., & Duca, F. A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2083-z · Cited by 216
“peaking 1–2 h following the onset of food intake [88], suggesting that PYY plays a role in controlling long-term”
BackgroundRozengurt, E. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00073.2006 · Cited by 222
“PYY is attracting intense interest because the peripheral administration of the PYY3–36 form of the peptide reduced food intake in mice, rats, and humans (2, 3) and, similar to bitter stimuli, evoked an aversive food response in mice (10).”
BackgroundEffects of PYY[3–36] in rodent models of diabetes and obesity
Pittner, R. A., Moore, C. X., Bhavsar, S. P., Gedulin, B. R., Smith, P. A., Jodka, C. M., Parkes, D. G., Paterniti, J. R., Srivastava, V. P., & Young, A. A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802696 · Cited by 219
Molecular evolution of NPY receptor subtypes
Larhammar, D., & Salaneck, E. (2004) · Neuropeptides · doi:10.1016/j.npep.2004.06.002 · Cited by 214
Appetite regulation and weight control: the role of gut hormones
Perry, B., & Wang, Y. (2012) · Nutrition & Diabetes · doi:10.1038/nutd.2011.21 · Cited by 217
Bleau, C., Karelis, A. D., St‐Pierre, D. H., & Lamontagne, L. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2617 · Cited by 215
“Studies conducted on humans feeding a HFD or obese subjects have reported increase of circulatory LPS and impaired intestinal barrier functions correlating with body mass index (BMI) [65,86–89].”
InfluentialLoktev, A. V., & Jackson, P. K. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.011 · Cited by 212
“Importantly, obese humans and diet-induced obese rodent models remain responsive to anorexigenic action of PYY3-36, suggesting that the lack of response in Bbip10 / mice is due to a defect in NPY2R receptor signaling rather than a secondary effect of obesity (Batterham et al., 2003; Pittner et al., 2004).”
BackgroundInfluentialThe obesity pipeline: current strategies in the development of anti-obesity drugs
Cooke, D., & Bloom, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 211
Self-citationWaddell, I. S., & Orfila, C. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2061909 · Cited by 211
“Batterham et al. (2003) demonstrated significantly low levels of PYY after fasting and after the consumption of a meal in obese individuals when compared with lean individuals ( p < 0.001).”
ResultInfluentialBudak, E., Fernández Sánchez, M., Bellver, J., Cerveró, A., Simón, C., & Pellicer, A. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.09.065 · Cited by 211
The role of gut hormones in the regulation of body weight and energy homeostasis
Karra, E., & Batterham, R. L. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.010 · Cited by 209
Self-citationHabituation as a determinant of human food intake.
Epstein, L. H., Temple, J. L., Roemmich, J. N., & Bouton, M. E. (2009) · Psychological Review · doi:10.1037/a0015074 · Cited by 211
“Peptide YY (Batterham et al., 2003; Batterham et al., 2002), which inhibits the release of neuropeptide Y, an appetite stimulant (Batterham et al., 2002) may be a reliable biomarker for satiation.”
BackgroundEffect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205
“PYY (total) In the type 2 diabetic and obese non-diabetic groups, the total PYY responses to the preload meal tended to be lower following pramlintide injection compared with those observed following placebo injection, although the differences in AUC0–1 h were not statistically significant (Fig.”
BackgroundResultInfluentialPeptide YY(1-36) and Peptide YY(3-36): Part I. Distribution, Release and Actions
Ballantyne, G. (2006) · Obesity Surgery · doi:10.1381/096089206776944959 · Cited by 204
Taste receptor signaling in the mammalian gut
Rozengurt, E., & Sternini, C. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.10.002 · Cited by 203
The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
Abu-Hamdah, R., Rabiee, A., Meneilly, G. S., Shannon, R. P., Andersen, D. K., & Elahi, D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1296 · Cited by 200
Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor
Ghigo, E., Broglio, F., Arvat, E., Maccario, M., Papotti, M., & Muccioli, G. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02160.x · Cited by 202
Acosta, A., Camilleri, M., Shin, A., Vazquez-Roque, M. I., Iturrino, J., Burton, D., O’Neill, J., Eckert, D., & Zinsmeister, A. R. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.020 · Cited by 200
Metabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Probiotics: How Effective Are They in the Fight against Obesity?
Mazloom, K., Siddiqi, I., & Covasa, M. (2019) · Nutrients · doi:10.3390/nu11020258 · Cited by 192
The regulation of food intake by the gut-brain axis: implications for obesity
Hussain, S. S., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.93 · Cited by 195
Self-citationBartz, S., Mody, A., Hornik, C., Bain, J., Muehlbauer, M., Kiyimba, T., Kiboneka, E., Stevens, R., Bartlett, J., St Peter, J. V., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4018 · Cited by 198
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
“A lack of effect of exendin(9-39) NH2 on food consumption has been reported in previous studies (42,43) and could be due to simultaneously increased levels of peptide YY (10,30,34,37), stimulating satiety (44).”
BackgroundChanges in Gastrointestinal Hormones and Leptin after Roux-en-Y Gastric Bypass Procedure: A Review
Beckman, L. M., Beckman, T. R., & Earthman, C. P. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2009.12.023 · Cited by 195
“As a result, it has been suggested that reduced PYY release is not likely to be a mechanism involved in the etiology of obesity (8,28).”
BackgroundResultInfluentialType 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors
Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.05.010 · Cited by 192
Ueda, S.-Y., Yoshikawa, T., Katsura, Y., Usui, T., Nakao, H., & Fujimoto, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0500 · Cited by 191
“One study demonstrated that the impact of infusion of exogenous PYY3–36 on subsequent caloric intake was similar in obese and lean subjects, suggesting that obese subjects are not resistant to anorexic effects of PYY (Batterham et al. 2003).”
BackgroundNarrative Review: Effect of Bariatric Surgery on Type 2 Diabetes Mellitus
Vetter, M. L., Cardillo, S., Rickels, M. R., & Iqbal, N. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-2-200901200-00007 · Cited by 192
“Basal and postprandial levels of PYY and ghrelin are lower in obese people than in lean people (47, 48) and may be even lower in diabetic people (49).”
BackgroundObesity: Pathophysiology and Intervention
Zhang, Y., Liu, J., Yao, J., Ji, G., Qian, L., Wang, J., Zhang, G., Tian, J., Nie, Y., Zhang, Y., et al. (2014) · Nutrients · doi:10.3390/nu6115153 · Cited by 189
“Thus, PYY replacement may be used to treat overweight and obesity [88,89].”
BackgroundThe neuropeptide Y system: Pathophysiological and therapeutic implications in obesity and cancer
Zhang, L., Bijker, M. S., & Herzog, H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.011 · Cited by 189
Brennan, I. M., Luscombe-Marsh, N. D., Seimon, R. V., Otto, B., Horowitz, M., Wishart, J. M., & Feinle-Bisset, C. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00478.2011 · Cited by 190
“However, evidence remains inconsistent; for example, while exogenous administration of PYY markedly suppresses energy intake in humans (3), this may reflect supraphysiological concentrations associated with nausea (18).”
BackgroundResultEffect of Human Body Weight Changes on Circulating Levels of Peptide YY and Peptide YY3–36
Pfluger, P. T., Kampe, J., Castaneda, T. R., Vahl, T., D’Alessio, D. A., Kruthaupt, T., Benoit, S. C., Cuntz, U., Rochlitz, H. J., Moehlig, M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1425 · Cited by 191
“584 J Clin Endocrinol Metab, February 2007, 92(2):583–588 Pfluger et al.”
InfluentialAntiobesity Pharmacotherapy: New Drugs and Emerging Targets
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.204 · Cited by 191
Causality of small and large intestinal microbiota in weight regulation and insulin resistance
Scheithauer, T. P. M., Dallinga-Thie, G. M., de Vos, W. M., Nieuwdorp, M., & van Raalte, D. H. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.002 · Cited by 188
“Ingestion of prebiotics increased the synthesis of GLP-1 and PYY in plasma of rodents and humans and was accompanied by reduced hunger rates [104].”
BackgroundInfluentialThe Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity
Bliss, E. S., & Whiteside, E. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00900 · Cited by 186
Moran, T. H., Smedh, U., Kinzig, K. P., Scott, K. A., Knipp, S., & Ladenheim, E. E. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00535.2004 · Cited by 189
“Running head: PYY(3-36) reduced food intake in rhesus monkeys”
InfluentialPeptide YY and Proglucagon mRNA Expression Patterns and Regulation in the Gut
Zhou, J., Hegsted, M., McCutcheon, K. L., Keenan, M. J., Xi, X., Raggio, A. M., & Martin, R. J. (2006) · Obesity · doi:10.1038/oby.2006.77 · Cited by 188
“PYY infusion resulted in decreased food intake in humans (14), monkeys (15), mice (16), and rats (17).”
BackgroundGibbons, C., Caudwell, P., Finlayson, G., Webb, D.-L., Hellström, P. M., Näslund, E., & Blundell, J. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3835 · Cited by 186
“PYY infusion has previously been shown to reduce food intake in normal-weight (6) and obese humans (21), and repeated administration to rodents has been shown to attenuate weight gain (6).”
BackgroundResultPeripheral administration of PYY3–36 produces conditioned taste aversion in mice
Halatchev, I. G., & Cone, R. D. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.02.003 · Cited by 191
Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity
Boey, D., Lin, S., Karl, T., Baldock, P., Lee, N., Enriquez, R., Couzens, M., Slack, K., Dallmann, R., Sainsbury, A., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0237-0 · Cited by 186
“Since circulating PYY levels are decreased in obese, hyperinsulinaemic people [37], our findings suggest that low circulating PYY concentrations may causally contribute to the development of hyperinsulinaemia and obesity, during ageing or under conditions of long-term consumption of a high-fat diet, respectively.”
BackgroundAbbott, C. R., Small, C. J., Kennedy, A. R., Neary, N. M., Sajedi, A., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.02.065 · Cited by 185
Self-citationEnergy intake and appetite are related to antral area in healthy young and older subjects
Sturm, K., Parker, B., Wishart, J., Feinle-Bisset, C., Jones, K. L., Chapman, I., & Horowitz, M. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.3.656 · Cited by 184
Little, T. J., Horowitz, M., & Feinle-Bisset, C. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.531 · Cited by 183
“Furthermore, in obese mice fed a very high-fat diet (58% of energy as fat), chronic infusion of PYY3–36 for a period of 7 d resulted in a sustained reduction in energy intake and body weight, which were associated with an increase in fat metabolism (10).”
InfluentialKalra, S. P., & Kalra, P. S. (2004) · Neuropeptides · doi:10.1016/j.npep.2004.06.003 · Cited by 182
Signalling from the periphery to the brain that regulates energy homeostasis
Kim, K.-S., Seeley, R. J., & Sandoval, D. A. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.8 · Cited by 183
Ueda, S.-Y., Yoshikawa, T., Katsura, Y., Usui, T., & Fujimoto, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0190 · Cited by 178
Harrold, J. A., Dovey, T. M., Blundell, J. E., & Halford, J. C. G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.007 · Cited by 177
“Yet, despite this controversy there is evidence that the peptide does not seem to have the same potency for restricting food intake in the obese (Batterham et al., 2003) suggestingweaker satiety signalling in obese individuals and a greater potential for overconsumption.”
Hazell, T. J., Islam, H., Townsend, L. K., Schmale, M. S., & Copeland, J. L. (2016) · Appetite · doi:10.1016/j.appet.2015.12.016 · Cited by 178
le Roux, C. W., Borg, C., Wallis, K., Vincent, R. P., Bueter, M., Goodlad, R., Ghatei, M. A., Patel, A., Bloom, S. R., & Aylwin, S. J. B. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181d3d21f · Cited by 176
“Total PYY-like immunoreactivity was measured with a specific and sensitive radioimmunoassay.(22,28,29) The assay detected changes of 2 pmol/L, with an intra-assay coefficient of variation (CV) of 5.”
MethodSelf-citationEmerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
Minireview: Gut Peptides Regulating Satiety
Druce, M. R., Small, C. J., & Bloom, S. R. (2004) · Endocrinology · doi:10.1210/en.2004-0089 · Cited by 177
“Like Oxm, GLP-1 is produced by processing of the proglucagon gene in the gut and the brain, and GLP-1 (7-36) amide is the active truncated form of this peptide (45–48).”
Self-citationAppetite signaling: From gut peptides and enteric nerves to brain
Näslund, E., & Hellström, P. M. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.017 · Cited by 173
“PYY(3-36) may mediate satiety sensations by acting directly on Y2 receptors in the arcuate nucleus of the hypothalamus [55].”
Alterations of sucrose preference after Roux-en-Y gastric bypass
Bueter, M., Miras, A. D., Chichger, H., Fenske, W., Ghatei, M. A., Bloom, S. R., Unwin, R. J., Lutz, T. A., Spector, A. C., & le Roux, C. W. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.07.025 · Cited by 173
“We confirmed that gastric bypass increases postprandial levels of the L-cell hormones GLP-1 and PYY in rats which have been shown to reduce hunger and enhance satiation [36,45,46].”
Self-citationBowels control brain: gut hormones and obesity
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.93 · Cited by 172
“48 Rodent studies also provide evidence of an anorectic synergy when IAPP is coadministered with either PYY(3-36) or cholecystokinin (CCK).”
Self-citationThe role of the gut/brain axis in modulating food intake
Sam, A. H., Troke, R. C., Tan, T. M., & Bewick, G. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.008 · Cited by 167
“…released from enteroendocrine L cells lining the distal GI tract in proportion to caloric intake (Adrian et al., 1985) Plasma levels of PYY rise within 30 min of a meal, and in humans, circulating levels plateau at 1e2 h post-prandially, remaining elevated for up to 6 h (Batterham et al., 2003a).”
BackgroundInfluentialŻwirska-Korczala, K., Konturek, S. J., Sodowski, M., Wyleżoł, M., Kuka, D., Sowa, P., Adamczyk-Sowa, M. H., Kukla, M., Berdowska, A., Rehfeld, J. F., et al. (2007) · PubMed · Cited by 168
Germain, N., Galusca, B., Le Roux, C. W., Bossu, C., Ghatei, M. A., Lang, F., Bloom, S. R., & Estour, B. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.4.967 · Cited by 169
“In this regard, recent reports suggest that PYY deficiency may contribute to the pathogenesis of obesity (31, 32).”
BackgroundSelf-citationPotential Hormone Mechanisms of Bariatric Surgery
Dimitriadis, G. K., Randeva, M. S., & Miras, A. D. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0276-5 · Cited by 167
Imaging of Brain Dopamine Pathways: Implications for Understanding Obesity
Wang, G.-J., Volkow, N. D., Thanos, P. K., & Fowler, J. S. (2009) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31819a86f7 · Cited by 166
Pharmacological Treatment of the Overweight Patient
Bray, G. A., & Greenway, F. L. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.2 · Cited by 165
“(Batterham et al., 2003).”
BackgroundKadouh, H., Chedid, V., Halawi, H., Burton, D. D., Clark, M. M., Khemani, D., Vella, A., Acosta, A., & Camilleri, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz140 · Cited by 166
Atypical Antipsychotic-Induced Weight Gain: Insights into Mechanisms of Action
Roerig, J. L., Steffen, K. J., & Mitchell, J. E. (2011) · CNS Drugs · doi:10.2165/11596300-000000000-00000 · Cited by 166
“The function of PYY is thought to be that of a satiety signal since exogenous administration of PYY3-36 reduces feeding and bodyweight in both humans and animals.([63,64]) Wang and Huang([62]) reported a reduction of PYY binding sites associated with olanzapine exposure.”
BackgroundMarciani, L., Wickham, M., Singh, G., Bush, D., Pick, B., Cox, E., Fillery-Travis, A., Faulks, R., Marsden, C., Gowland, P. A., et al. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00452.2006 · Cited by 167
“Peptide YY and glucagon-like peptide-1 are other peptides, located more distally, released by nutrients including fat, infusion of which, like CCK, inhibits gastric emptying and feeding (1, 39).”
BackgroundIoannides-Demos, L. L., Proietto, J., & McNeil, J. J. (2005) · Drugs · doi:10.2165/00003495-200565100-00006 · Cited by 165
Diepvens, K., Häberer, D., & Westerterp-Plantenga, M. (2008) · International Journal of Obesity · doi:10.1038/sj.ijo.0803758 · Cited by 164
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1806 · Cited by 163
Mechanism Underlying the Weight Loss and Complications of Roux-en-Y Gastric Bypass. Review
Abdeen, G., & le Roux, C. (2016) · Obesity Surgery · doi:10.1007/s11695-015-1945-7 · Cited by 162
“gastric banding (AGB) surgery in humans [51] or sham operations in rats [56].”
BackgroundGastrointestinal targets of appetite regulation in humans
Delzenne, N., Blundell, J., Brouns, F., Cunningham, K., De Graaf, K., Erkner, A., Lluch, A., Mars, M., Peters, H. P. F., & Westerterp‐Plantenga, M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00707.x · Cited by 162
“All three members of the family influence food intake, NPY acts as orexigenic peptide, PP from the pancreas has a satiety effect (152).”
BackgroundNew Drug Targets for the Treatment of Obesity
Powell, A. G., Apovian, C. M., & Aronne, L. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.82 · Cited by 161
Fulton, S. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.10.003 · Cited by 159
“Released from intestinal cells in proportion to caloric intake, peptide YY (PYY) is another gut peptide implicated in appetite control [30,31].”
BackgroundFeinle-Bisset, C., Patterson, M., Ghatei, M. A., Bloom, S. R., & Horowitz, M. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00220.2005 · Cited by 160
“There is persuasive evidence that ghrelin, PYY, and PP play a role in the regulation of food intake, ghrelin as a stimulant (8, 42), and PYY and PP as suppressants (4, 5).”
BackgroundMethodSelf-citationGhrelin, the peripheral hunger hormone
Higgins, S. C., Gueorguiev, M., & Korbonits, M. (2007) · Annals of Medicine · doi:10.1080/07853890601149179 · Cited by 160
“It has also been suggested that PYY may have a role to play in the reduction of ghrelin levels after food intake (158).”
BackgroundBouret, S., Levin, B. E., & Ozanne, S. E. (2015) · Physiological Reviews · doi:10.1152/physrev.00007.2014 · Cited by 157
Kloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 197
Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking
Shalev, U., Erb, S., & Shaham, Y. (2010) · Brain Research · doi:10.1016/j.brainres.2009.07.028 · Cited by 153
“There is evidence that systemic PYY3-36 injections decrease food intake inmice, rats, monkeys, and humans (Batterham et al., 2002, 2003; Moran et al., 2005, but see Boggiano et al., 2005).”
BackgroundEffects of Antipsychotic Medications on Appetite, Weight, and Insulin Resistance
Deng, C. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.05.006 · Cited by 151
Obesity-Associated Hypertension: Recent Progress in Deciphering the Pathogenesis
Rahmouni, K. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.00920 · Cited by 150
Kral, J. G., & Näslund, E. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0563 · Cited by 151
“Peptide YY decreased food intake in obese humans when it was given in a truncated formulation (peptide YY 3–36 )”
BackgroundMolecular Mechanisms of Appetite Regulation
Yu, J. H., & Kim, M.-S. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.6.391 · Cited by 148
“Infusion of PYY3-36 in humans reduced consumption of food during test meals [44].”
BackgroundDiet and Gastrointestinal Bypass–Induced Weight Loss
Chandarana, K., Gelegen, C., Karra, E., Choudhury, A. I., Drew, M. E., Fauveau, V., Viollet, B., Andreelli, F., Withers, D. J., & Batterham, R. L. (2011) · Diabetes · doi:10.2337/db10-0566 · Cited by 150
“In obese human subjects, reduced circulating PYY concentrations result in diminished satiety (4), whereas PYY administration to obese subjects decreases caloric intake (2).”
BackgroundResultInfluentialSelf-citationHellström, P. M., Geliebter, A., Näslund, E., Schmidt, P. T., Yahav, E. K., Hashim, S. A., & Yeomans, M. R. (2004) · British Journal of Nutrition · doi:10.1079/bjn20041142 · Cited by 149
“Furthermore, infusion of physiologically appropriate of PYY3-36 decreased rated appetite and reduced daily food intake (Batterham, 2002) in normal and obese subjects (Batterham et al. 2003).”
Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men
Schmidt, J. B., Gregersen, N. T., Pedersen, S. D., Arentoft, J. L., Ritz, C., Schwartz, T. W., Holst, J. J., Astrup, A., & Sjödin, A. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00569.2013 · Cited by 146
“Whereas GLP-1-mediated insulin secretion is supported by a substantial body of literature (21), both negative and no effects of PYY3–36 on insulin secretion have been reported (5, 42).”
BackgroundResultInfluentialVrang, N., Madsen, A. N., Tang-Christensen, M., Hansen, G., & Larsen, P. J. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00726.2005 · Cited by 147
“humans (6, 7) and no signs of nausea when PYY(3–36) was”
BackgroundResultPeptide YY Is a Regulator of Energy Homeostasis in Obese Children before and after Weight Loss
Roth, C. L., Enriori, P. J., Harz, K., Woelfle, J., Cowley, M. A., & Reinehr, T. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1357 · Cited by 146
Central Nervous System Regulation of Food Intake
Schwartz, M. W. (2006) · Obesity · doi:10.1038/oby.2006.275 · Cited by 145
Vitaglione, P., Lumaga, R. B., Stanzione, A., Scalfi, L., & Fogliano, V. (2009) · Appetite · doi:10.1016/j.appet.2009.07.013 · Cited by 164
Pharmacological management of appetite expression in obesity
Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.19 · Cited by 156
NPY receptors as potential targets for anti‐obesity drug development
Yulyaningsih, E., Zhang, L., Herzog, H., & Sainsbury, A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01363.x · Cited by 138
“Indeed, short-term i.v. administration of PP to lean human subjects led to sustained suppression of appetite and food intake up to 24 h post-infusion (Batterham et al., 2003b; Jesudason et al., 2007.”
BackgroundResultInfluentialTHE CRITICAL ROLE OF THE MELANOCORTIN SYSTEM IN THE CONTROL OF ENERGY BALANCE
Seeley, R. J., Drazen, D. L., & Clegg, D. J. (2004) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.24.012003.132428 · Cited by 143
Physiological, pathological and potential therapeutic roles of ghrelin
Leite-Moreira, A. F., & Soares, J. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.02.009 · Cited by 164
Weight regain after Roux-en-Y: A significant 20% complication related to PYY
Meguid, M. M., Glade, M. J., & Middleton, F. A. (2008) · Nutrition · doi:10.1016/j.nut.2008.06.027 · Cited by 153
“PYY[3–36] administration decreases the respiratory quotient and”
BackgroundInfluentialEmerging Therapeutic Strategies for Obesity
Foster-Schubert, K. E., & Cummings, D. E. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0041 · Cited by 142
“Although the catabolic effects of peripheral PYY3-36 are somewhat subtle and subject to vicissitudes of experimental conditions in rodents (101), these effects may be more robust in primates (102), and PYY3-36 administration in humans has been reported to lessen hunger and decrease single-meal food intake by 36%, with…”
BackgroundThe electrophysiology of feeding circuits
Jobst, E. E., Enriori, P. J., & Cowley, M. A. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.10.007 · Cited by 159
Effect of fat saturation on satiety, hormone release, and food intake
Maljaars, J., Romeyn, E. A., Haddeman, E., Peters, H. P. F., & Masclee, A. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27335 · Cited by 162
“Whereas many studies failed to confirm the results of Batterham et al (33), adequate habituation and acclimatization of animals proved to be essential in these studies, and PYY is considered to be a physiologic satiety signal (34).”
BackgroundGut hormones: Implications for the treatment of obesity
Neary, M. T., & Batterham, R. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.005 · Cited by 158
Self-citationObesity and the role of gut and adipose hormones in female reproduction
Gosman, G. G., Katcher, H. I., & Legro, R. S. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml024 · Cited by 139
“Obese individuals have lower endogenous levels of PYY than those observed in lean subjects (Batterham et al., 2003).”
Influential
Metadata
- Authors
- Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 941-948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170277935
- Cited by
- 1,604
- References
- 27
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 31 · 2023: 29 · 2022: 33 · 2021: 54 · 2020: 40 · 2019: 63 · 2018: 44 · 2017: 61 · 2016: 61 · 2015: 60 · 2014: 78 · 2013: 83 · 2012: 89
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- PYY3-36, peptide YY, obesity, dietary intake, appetite, ghrelin, leptin resistance, gastrointestinal hormones, hypothalamic regulation of appetite, body mass index, energy intake
- MeSH terms
- Appetite, Double-Blind Method, Eating, Female, Humans, Insulin, Male, Obesity, Peptide Fragments, Cross-Over Studies, Peptide YY, Leptin, Peptide Hormones, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.